| Literature DB >> 32776794 |
Jianyong Lv1, Cuiyuan Huang1, Zuofeng Wang1, Shan Ou1.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of the addition of local infiltration analgesia (LIA) to adductor canal block (ACB) for pain control after primary total knee arthroplasty (TKA).Entities:
Keywords: Total knee arthroplasty; adductor canal block; local infiltration analgesia; meta-analysis; opioid
Mesh:
Substances:
Year: 2020 PMID: 32776794 PMCID: PMC7557703 DOI: 10.1177/0300060520926075
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Flow diagram of the search strategy used to identify eligible studies for inclusion in a meta-analysis to evaluate the efficacy and safety of the addition of local infiltration analgesia to adductor canal block for pain control after primary total knee arthroplasty.
Characteristics of the six studies included in a meta-analysis to evaluate the efficacy and safety of the addition of local infiltration analgesia (LIF) to adductor canal block (ACB) for pain control after primary total knee arthroplasty.[9–14]
| Author | Design | Mean age, years | Sample size | Sex, female | Intervention of ACB+LIA | Intervention of ACB |
|---|---|---|---|---|---|---|
| Sawhney et al., 2016[ | RCT | 66/68 | 46/50 | 26/29 | 110 ml normal saline solution containing 300 mg ropivacaine, 10 mg morphine and 30 mg ketorolac | 30 ml of 0.5% ropivacaine |
| Gwam et al., 2017[ | Non-RCT | 63/63 | 52/75 | 33/53 | 50 ml saline solution containing 30 ml of 0.25% bupivacaine, with 1: 200 000 parts epinephrine, 8 mg of dexamethasone, 2 mg of morphine and 30 mg of ketorolac | 10 ml 0.75% ropivacaine |
| Zhou et al., 2018[ | RCT | 67/66 | 20/20 | 13/14 | 100 ml ropivacaine 2 mg/ml with epinephrine 0.5 ml 1 mg/ml | 30 ml of 0.375% ropivacaine with 5 µg/ml epinephrine |
| Sankineani et al., 2018[ | Non-RCT | 67/65 | 100/100 | 30/20 | 60 ml saline solution containing 30 ml of 0.2% ropivacaine, 40 mg ketorolac, 0.5 ml of adrenaline, 4 mg of morphine sulphate | 20 ml of 0.2% ropivacaine |
| Sankineani et al., 2018[ | Non-RCT | 61/60 | 60/60 | 18/22 | 15 ml of 0.2% ropivacaine | 20 ml of 0.2% ropivacaine |
| Kampitak et al., 2018[ | RCT | 56/54 | 30/30 | 8/9 | 100 ml saline solution containing 0.5% levobupivacaine 20 ml, morphine 5 mg, adrenaline 0.3 mg | 20 ml of 0.5% levobupivacaine |
RCT, randomized controlled trial.
Quality assessment of the three randomized controlled trials using the modified Jadad score.[9–11]
| Study | Scores for individual domains | Total score | |||
|---|---|---|---|---|---|
| Randomization | Concealment of allocation | Double blinding | Withdrawals and dropouts | ||
| Sawhney et al., 2016[ | 2 | 2 | 2 | 1 | 7 |
| Zhou et al., 2018[ | 2 | 2 | 2 | 1 | 7 |
| Kampitak et al., 2018[ | 2 | 1 | 0 | 1 | 4 |
Quality assessment of the three non-randomized controlled trials using the Methodological Index for Non-Randomized Studies scale.[12–14]
| Item | Study | ||
|---|---|---|---|
| Gwam et al., 2017[ | Sankineani et al., 2018[ | Sankineani et al., 2018[ | |
| A clearly stated aim | 2 | 2 | 2 |
| Inclusion of consecutive patients | 2 | 2 | 2 |
| Prospective data collection | 2 | 2 | 2 |
| Endpoints appropriate to the aim of the study | 2 | 2 | 2 |
| Unbiased assessment of the study endpoint | 0 | 0 | 0 |
| A follow-up period appropriate to the aims of study | 2 | 2 | 1 |
| Less than 5% loss to follow-up | 2 | 2 | 2 |
| Prospective calculation of the sample size | 0 | 1 | 0 |
| An adequate control group | 2 | 2 | 2 |
| Contemporary groups | 1 | 0 | 0 |
| Baseline equivalence of groups | 2 | 2 | 2 |
| Adequate statistical analyses | 2 | 2 | 2 |
| Total score | 19 | 19 | 17 |
Figure 2.Forest plot of the meta-analysis of pain score on postoperative day (POD) 0–2. SMD, standard mean difference; CI, confidence interval.[9–14]
Figure 3.Forest plot of the meta-analysis of opioid consumption on postoperative day (POD) 0–2. SMD, standard mean difference; CI, confidence interval.[10,11,14]
Results of other study outcomes in a meta-analysis to evaluate the efficacy and safety of the addition of local infiltration analgesia to adductor canal block for pain control after primary total knee arthroplasty.
| Study outcomes | SMD or OR (95% CI) | Heterogeneity | |
|---|---|---|---|
| Range of motion | SMD = 0.131 (–0.062, 0.323) | ||
| Length of hospitalization | SMD = 0.001 (–0.218, 0.221) | ||
| Nausea | OR = 0.522 (0.282, 0.968) | ||
| Vomiting | OR = 0.780 (0.417, 1.458) | ||
| Pruritus | OR = 0.709 (0.253, 0.966) |
SMD, standard mean difference; OR, odds ratio; CI, confidence interval.
Figure 4.Sensitivity analysis of pain score on postoperative day 0.